SYGG.F Share Price Performance
Recent SYGG.F News & Updates
No updates
Synairgen plc Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0063
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Synairgen plc Competitors
About SYGG.F
- Founded
- 2004
- Employees
- 36
- CEO
- WebsiteView website
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
U.K. Market Performance
- 7 Days: -4.2%
- 3 Months: 15.6%
- 1 Year: 7.7%
- Year to Date: 10.3%
Over the last 7 days, the market has dropped 4.2%, driven by a loss of 5.7% in the Energy sector. In the last year, the market is actually up 7.7%. Earnings are forecast to grow by 14% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading